Hims & Hers Health (HIMS) Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HIMS shares.
View HIMS analyst ratings or view top-rated stocks.

10 brokerages have issued 12 month target prices for Hims & Hers Health's stock. Their HIMS share price forecasts range from $5.00 to $18.00. On average, they expect the company's stock price to reach $11.75 in the next year. This suggests a possible upside of 88.9% from the stock's current price.
View analysts price targets for HIMS or view top-rated stocks among Wall Street analysts.

Hims & Hers Health's stock was trading at $6.41 on January 1st, 2023. Since then, HIMS shares have decreased by 3.0% and is now trading at $6.22.
View the best growth stocks for 2023 here.

Hims & Hers Health saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 16,650,000 shares, a decrease of 5.8% from the August 15th total of 17,680,000 shares. Based on an average daily trading volume, of 2,990,000 shares, the short-interest ratio is currently 5.6 days. Approximately 12.4% of the company's stock are sold short.
View Hims & Hers Health's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our HIMS earnings forecast.

Hims & Hers Health, Inc. (NYSE:HIMS) released its quarterly earnings results on Monday, August, 7th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.03. The firm earned $207.91 million during the quarter, compared to analyst estimates of $204.95 million. Hims & Hers Health had a negative trailing twelve-month return on equity of 14.97% and a negative net margin of 6.61%. The firm's quarterly revenue was up 83.1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.10) EPS.

ETFs with the largest weight of Hims & Hers Health (NYSE:HIMS) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Global X Telemedicine & Digital Health ETF (EDOC), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Amplify Online Retail ETF (IBUY), Fidelity Digital Health ETF (FDHT) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF).

Hims & Hers Health issued an update on its third quarter 2023 earnings guidance on Monday, August, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $217.00 million-$222.00 million, compared to the consensus revenue estimate of $213.78 million.

Hims & Hers Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "HIMS."

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HIMS stock can currently be purchased for approximately $6.22.

Hims & Hers Health (NYSE:HIMS) has a market capitalization of $1.31 billion and generates $526.92 million in revenue each year. The company earns $-65,680,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

The company employs 651 workers across the globe.

Hims & Hers Health's mailing address is 2269 CHESTNUT STREET SUITE 523, SAN FRANCISCO CA, 94123. The official website for the company is www.forhims.com. The company can be reached via phone at 415-851-0195 or via email at hims-ir@westwicke.com.